BDTX Black Diamond Therapeutics, Inc. Insider Trading

BIOTECH GROWTH N V (10% holder) sells 5.78M shares for $12.0M at avg $2.07; stock now $1.88, down 74.6% from 52-week high

BIOTECH GROWTH N V, a 10% owner, executed 7 separate sales totaling 5,784,292 shares on 2025-03-19 for $11,997,749.13, reducing holdings by 67.9% from 8.52M to 2.73M shares. The blended average transaction price was $2.07, while the current market price sits at $1.88, a decline from the sale prices. The stock is down 74.6% from its 52-week high of $7.39, and Black Diamond Therapeutics reported a net loss of $15,557,000.00 over its most recent full fiscal year. This large-scale reduction of a major equity stake in an unprofitable biotech company at prices that have since fallen further, combined with the company's negative earnings trajectory, underscores significant deterioration in company fundamentals between the insider's transaction date and the current market valuation.

Versant Venture Capital VI sold 221,600 shares of BDTX at $6.32; retains 3,726,341 shares (-5.6% from pre-transaction holdings).

Versant Venture Capital VI, a substantial 10% shareholder, executed a partial reduction of its position, selling 221,600 shares at $6.32 on 2024-08-28 while maintaining a significant stake of 3,726,341 shares. The company remains unprofitable with net income of $-19,909,000.00 and a market cap of $344,679,859.50; the stock has declined 17.5% from its 52-week high of $7.39, though it has appreciated 27.6% over the past 90 days. The sale represents a modest -5.6% reduction from pre-transaction holdings, suggesting a measured rather than aggressive exit. The transaction occurred within the stock's recent upward momentum context, with the current price of $6.10 near the transaction price of $6.32.